Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyTreg Immunotherapy in Islet Transplantation
NCT03444064Phase 1Completed
- Sponsor
- University of Alberta
- Start
- Feb 2018
- Primary completion
- Aug 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Polyclonal Regulatory T Cells in type 1 diabetes mellitus (T1D) (2 arms), sponsored by University of Alberta. Primary endpoint: Adverse Events at 58 weeks. Started Feb 2018; status: completed.
02
Drugs
Polyclonal Regulatory T Cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03444064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444064.